SCHEMBL6118259

SCHEMBL6118259

COc1ccc2[nH]c(-c3ccc(F)cc3)cc2c1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.72
KMT2A Q03164 4/20 0.72
NPC1 O15118 4/20 0.72
RAB9A P51151 4/20 0.72
MEN1 O00255 3/20 0.72
MAPT P10636 2/20 0.72
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
CASP3 P42574 1/20 0.60
SENP8 Q96LD8 1/20 0.60
SENP7 Q9BQF6 1/20 0.60
SENP6 Q9GZR1 1/20 0.60
ALDH1A1 P00352 4/20 0.58
HPGD P15428 3/20 0.58
FLT3 P36888 2/20 0.56
AXL P30530 1/20 0.54
USP2 O75604 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264688 0.90 KDM4E (0.81) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL15060416 0.88 KDM4E (0.68) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL15058692 0.86 KDM4E (0.74) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL15058186 0.84 KDM4E (0.72) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL15059222 0.84 KDM4E (0.72) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL10793244 0.84 KDM4E (0.72) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL1429201 0.84 NPC1 (1.00) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL15058477 0.84 KDM4E (0.67) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL6117781 0.84 KDM4E (0.71) KDM4EKMT2ANPC1RAB9AMEN1
SCHEMBL10799107 0.82 KDM4E (0.73) KDM4EKMT2ANPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680120-B2 Indole derivative or pharmaceutically acceptable salt thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 US disclosed
US-8680120-B2 Indole derivative or pharmaceutically acceptable salt thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 US disclosed
US-8680120-B2 Indole derivative or pharmaceutically acceptable salt thereof KISSEI PHARMACEUTICAL CO., LTD. (JP) 2014-03-25 US disclosed
EP-2460791-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2012-06-06 EP disclosed
EP-2460791-A1 INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF Kissei Pharmaceutical Co., Ltd. (JP) 2012-06-06 EP disclosed
US-20120129890-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-24 US disclosed
US-20120129890-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-24 US disclosed
US-20120129890-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF KISSEI PHARMACEUTICAL CO., LTD. (JP) 2012-05-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120129890-A1 INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF PTGER1, CYSLTR1, ARRB1 KDM4E 3321/4885KMT2A 2189/4885NPC1 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.